Direct to Consumer Biomarker Testing for Alzheimer Disease —Are We Ready for the Insurance Consequences?

This Viewpoint discusses direct-to-consumer biomarker tests for Alzheimer disease and their implications on future insurance coverage.
Source: JAMA Neurology - Category: Neurology Source Type: research